Page 10«..9101112..2030..»

You are currently browsing the Nano Medicine category

‘Nanomedicine’: Potentially revolutionary class of drugs are made-in … – CTV News

§ August 4th, 2017 § Filed under Nano Medicine Comments Off on ‘Nanomedicine’: Potentially revolutionary class of drugs are made-in … – CTV News

It's rare for researchers to discover a new class of drugs, but a University of Calgary microbiology professor recently did so -- by accident and now hopes to revolutionize autoimmune disease treatment.

In 2004, Dr. Pere Santamaria and his research lab team at the Cumming School of Medicine conducted an experiment to image a mouse pancreas, using nanoparticles coated in pancreatic proteins.

The work didnt go as planned.

Our experiment was a complete failure, he recently told CTV Calgary. We were actually quite depressed, frustrated about the outcome of that.

But the team was surprised to discover the nanoparticles had a major effect on the mice: resetting their immune systems.

The team realized that, by using nanoparticles, they can deliver disease-specific proteins to white blood cells, which will then go on to reprogram the cells to actively suppress the disease.

Whats more, the nanoparticles stop the disease without compromising the immune system, as current treatments often do.

Santamarias team believes nanomedicine drugs can be modified to treat all kinds of autoimmune and inflammatory diseases, including Type 1 diabetes, multiple sclerosis and rheumatoid arthritis.

Convinced that nanomedicine has the potential to disrupt the pharmaceutical industry, Santamaria founded a company to explore the possibilities, called Parvus Therapeutics Inc.

This past spring, Novartis, one of the worlds largest pharmaceutical companies, entered into a license and collaboration agreement with Parvus to fund the process of developing nanomedicine.

Under the terms of the agreement, Parvus will receive research funding to support its clinical activities, while Novartis receives worldwide rights to use Parvus technology to develop and commercialize products for the treatment of type 1 diabetes.

Its a good partnership, Santamaria said in a University of Calgary announcement. Bringing a drug to market requires science as well as money.

Santamaria cant say how long it might be before nanomedicine can be used to create human therapies, but he says everyone involved is working aggressively to make it happen.

With a report from CTV Calgarys Kevin Fleming

Read this article:
'Nanomedicine': Potentially revolutionary class of drugs are made-in ... - CTV News

Read the Rest...

UCalgary researcher signs deal to develop nanomedicines for … – UCalgary News

§ August 4th, 2017 § Filed under Nano Medicine Comments Off on UCalgary researcher signs deal to develop nanomedicines for … – UCalgary News

When Dr. Pere Santamaria arrived in Calgary in 1992 to join the Cumming School of Medicine, he never could have imagined he would make a groundbreaking discovery that would lead to a spinoff company. When I arrived, I found out that the grant money I was expecting hadnt come through, says Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases and member of the Snyder Institute for Chronic Diseases. So I had an empty lab with no research assistants and no salary. I had to beg my supervisor to give me $10,000 to start my research.

Despite the rocky start, Santamaria has achieved something many scientists dream of making a discovery that has practical applications for health care. Santamarias discovery revolves around the use of nanoparticles coated in proteins to treat autoimmune and inflammatory disorders.

They can be modified for different diseases, such as Type 1 diabetes, multiple sclerosis and rheumatoid arthritis without compromising the entire immune system, Santamaria explains. Instead, they basically work to reset the immune system.

Nanomedicines unique mechanism has the potential to disrupt the pharmaceutical industry entirely. Developing a new class of drugs is rare. With the assistance of Innovate Calgary, Santamaria started a company, Parvus Therapeutics Inc., to represent the technology and explore ways of bringing it to market. Announced in April 2017, Parvus entered into an exclusive deal with the Swiss pharma giant Novartis, hopefully leading to the development and commercialization of Parvuss nanomedicine to treat Type 1 diabetes.

Its a good partnership, Santamaria says. Bringing a drug to market requires science as well as money.

Supporting commercialization should be a top priority for all research, he continues. Our biggest responsibility is to the patients and making sure they have access to the medicine they need. With that in mind, Santamaria shares his insight for other researchers who may be interested in bringing their discoveries from the lab bench to the market.

If youre interested in investigating spin-out opportunities, get in touch with Innovate Calgary, which offers mentors, coaching, business skill development programs, intellectual property services and other back-office support.

Throughout the years, Santamarias work has been funded by numerous organizations, including Diabetes Canada, the Juvenile Diabetes Research Foundation, the Canadian Institutes of Health Research (CIHR) and the Diabetes Association, Foothills.He is a member of the Snyder Institute and associate member of the Hotchkiss Brain Institute.Santamaria named his company Parvus from the Greek word meaning small.

Here is the original post:
UCalgary researcher signs deal to develop nanomedicines for ... - UCalgary News

Read the Rest...

‘Blazing the trail’: University of Calgary research could lead to cures for autoimmune diseases – CBC.ca

§ August 3rd, 2017 § Filed under Nano Medicine Comments Off on ‘Blazing the trail’: University of Calgary research could lead to cures for autoimmune diseases – CBC.ca

Researchers at the University of Calgary say their work in the field of "nanomedicine"could lead to cures for Type 1 diabetes, multiple sclerosis and many more diseases.

Dr. Pere Santamaria said the process involves "nanoparticles" thousands of times smaller than a typicalhuman cell that could be used to stop the body from attacking itself.

That, he said, could potentially lead to cures for autoimmunedisorders.

"There are no drugs that can do that today,"said Santamaria, aprofessor ofimmunology at the University of Calgary.

"Other drugs that are being used to treat chronic inflammatory disorders impair the ability of the immune system to do its job, so there are secondary effects and longterm complications our drugs don't do that."

Pharmaceutical company Novartis has partnered with Santamaria's own company, Parvus Therapeutics, to work on developing the nanomedicines and take the drugs to market.

Now with support and funding, Santamariasaid the new drug"has the potential to revolutionizemedicine" if the drugs pass clinical testing.

Santamariasaid autoimmune disordersarecaused by white blood cells attacking the tissues in a person'sown body.

Pharmaceutical company Novartis has partnered with Dr. Santamaria's Parvus Therapeutics to work on developing nanomedicines to cure autoimmune disorders and take the drugs to market. (CBC)

Type 1 diabetesis treatable with insulin, but there is no cure. It's the same for many other diseases.

"Our drugs aim to resolve the inflammation of the tissue, the attack of the tissue, and resolve that process altogether," Santamaria said.

He said the nanoparticles could halt disorders without impairing the rest of the immune system.

"So we can reset the immune system to its steady state that means the healthy state without impairing the ability of our immune system to protect us against infections and cancer,"Santamariasaid.

Santamaria said the nanoparticleswere discovered during an experiment years ago, and the initialtestresults"made nosensewhatsoever." Since that day, the nanomedicines havebeen in development and he credits the progress to curiosity.

"We almost shoved them under the rug," Santamaria said."We didn't do that. Fortunately, we were pursued wth curiosity of researching."

Santamaria said the process of taking a discovery from the research laboratory to the marketplace is enormously complex and the drug has yet to go through preclinical trials.

Because nanomedicine is such a new field of research, there is no firm timeline on when the medicinescould be available if they pass human trials.

"Our nanomedicineis a new class of drug ... so we're basically blazing the trail," Santamaria said.

"We hope that we can carry that torch and be an example for all the investigators that might follow suit, that may run into discoveries such as the ones that we've made and hopefully they can follow in our footsteps."

Read more:
'Blazing the trail': University of Calgary research could lead to cures for autoimmune diseases - CBC.ca

Read the Rest...

UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes – UCalgary News

§ August 1st, 2017 § Filed under Nano Medicine Comments Off on UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes – UCalgary News

When Dr. Pere Santamaria arrived in Calgary in 1992 to join the Cumming School of Medicine, he never could have imagined he would make a groundbreaking discovery that would lead to a spinoff company. When I arrived, I found out that the grant money I was expecting hadnt come through, says Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases and member of the Snyder Institute for Chronic Diseases. So I had an empty lab with no research assistants and no salary. I had to beg my supervisor to give me $10,000 to start my research.

Despite the rocky start, Santamaria has achieved something many scientists dream of making a discovery that has practical applications for health care. Santamarias discovery revolves around the use of nanoparticles coated in proteins to treat autoimmune and inflammatory disorders.

They can be modified for different diseases, such as Type 1 diabetes, multiple sclerosis and rheumatoid arthritis without compromising the entire immune system, Santamaria explains. Instead, they basically work to reset the immune system.

Nanomedicines unique mechanism has the potential to disrupt the pharmaceutical industry entirely. Developing a new class of drugs is rare. With the assistance of Innovate Calgary, Santamaria started a company, Parvus Therapeutics Inc., to represent the technology and explore ways of bringing it to market. Announced in April 2017, Parvus entered into an exclusive deal with the Swiss pharma giant Novartis, hopefully leading to the development and commercialization of Parvuss nanomedicine to treat Type 1 diabetes.

Its a good partnership, Santamaria says. Bringing a drug to market requires science as well as money.

Supporting commercialization should be a top priority for all research, he continues. Our biggest responsibility is to the patients and making sure they have access to the medicine they need. With that in mind, Santamaria shares his insight for other researchers who may be interested in bringing their discoveries from the lab bench to the market.

If youre interested in investigating spin-out opportunities, get in touch with Innovate Calgary, which offers mentors, coaching, business skill development programs, intellectual property services and other back-office support.

Throughout the years, Santamarias work has been funded by numerous organizations, including Diabetes Canada, the Juvenile Diabetes Research Foundation, the Canadian Institutes of Health Research (CIHR) and the Diabetes Association, Foothills.He is a member of the Snyder Institute and associate member of the Hotchkiss Brain Institute.Santamaria named his company Parvus from the Greek word meaning small.

Continue reading here:
UCalgary researcher signs deal to develop nanomedicines for treatment of Type 1 diabetes - UCalgary News

Read the Rest...

Application of Nanomaterials in the Field of Medicine – Medical News Bulletin

§ July 31st, 2017 § Filed under Nano Medicine Comments Off on Application of Nanomaterials in the Field of Medicine – Medical News Bulletin

There has been a growing interest in the different applications of nanomaterials in the field of medicine. An article published in Nanomedicine: Nanotechnology, Biology, and Medicine showed the ways in which Laponite, a synthetic clay made of nanomaterials, can be of use in clinical practice.

Current advances in technology have provided many opportunities to develop new devices that improve the practice of medicine. There has been a growing interest in the different applications of nanomaterials in the field of medicine.

An article published in Nanomedicine: Nanotechnology, Biology, and Medicine reviewed Laponite, a non-toxic synthetic clay composed of nanomaterials which has different uses in the field of medicine. Laponite can be used in drug delivery systems, as the synthetic clay protects substances from degradation in physiologic environments. Different experiments show that Laponite is effective not only in protecting drugs from degradation, but also in transporting and releasing drugs into the body. The degradation of Laponite in the physiologic environment also releases products which have biological roles, especially in bone formation.

Laponite has been shown to induce osteogenic differentiation of cells in the absence of other factors which are known to promote differentiation and cell growth. The application of nanomaterials in bioimaging has also been studied. In one experiment, Laponite was incorporated with gadolinum, a dye used in magnetic resonance imaging (MRI), resulting in brighter images and prolonged contrast enhancement for 1 hour post-injection. Laponite has also proven to be of use in the field of regenerative medicine and tissue engineering. This synthetic clay can elicit specific biologic responses, act as a carrier for biochemical factors, and improve the mechanical properties of scaffolds used for tissue growth.

In summary, nanomaterials and synthetic clays such as Laponite have many applications in the field of medicine. Although current published literature state no toxic effects on the human body, further studies are needed to assess safety before it can be applied to clinical practice.

Written By:Karla Sevilla

Add to Flipboard Magazine.

Originally posted here:
Application of Nanomaterials in the Field of Medicine - Medical News Bulletin

Read the Rest...

International Conference and Exhibition on Nanomedicine and Nanotechnology – Technology Networks

§ July 31st, 2017 § Filed under Nano Medicine Comments Off on International Conference and Exhibition on Nanomedicine and Nanotechnology – Technology Networks

Short Name: Nanomed Meeting 2017

Theme: Challenges and Innovations in next generation medicine

Website: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology

Registration Link: http://www.meetingsint.com/pharma-conferences/nanomedicine-nanotechnology/registration

Nanomed Meeting 2017 Organizing Committee invites you to attend the largest assemblage of Nanomedicine and Nanotechnology researchers from around the globe during November 23-24, 2017 at Dubai, UAE.

Nanomed Meeting 2017 is a global annual event. This International Conference and Exhibition on Nanomedicine and Nanotechnology brings together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. The passage of Nanomed Meeting 2017 through a decade at Asia finds much requirement for discussion also focusing the latest developments in the field of Nanomedicine and Nanotechnology.

Why attend?

Join your peers around the world focused on learning about Nanomedicine and Nanotechnology related advances, which is your single best opportunity to reach the largest assemblage of participants from the Nanomedicine and Nanotechnology community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 2-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Nanomedicine and Nanotechnology are hallmarks of this conference.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Visit link:
International Conference and Exhibition on Nanomedicine and Nanotechnology - Technology Networks

Read the Rest...

Cancer survivor becomes a cancer fighter at a Philly start-up – Philly.com

§ July 31st, 2017 § Filed under Nano Medicine Comments Off on Cancer survivor becomes a cancer fighter at a Philly start-up – Philly.com

What Debra Travers really wanted to be was a marine biologist, until I found out Jacques Cousteau wasnt hiring.

How she wound up as chief executive of PolyAurum LLC, a Philadelphia start-up developing biodegradable gold nanoparticles for treating cancerous tumors, involved a professional journey of more than 30 years in pharmaceutical and diagnostics industries, and a personal battle with the disease shes now in business to defeat.

After determining that studying sea creatures was not a viable career choice, Travers a military kid from all over switched her major at Cedar Crest College in Allentown to medical technology. She graduated in 1979, then worked for three years in a hospital laboratory until she concluded she didnt like shift work and could do more.

What followed was an impressive career progression: Travers started as a chemistry technician at DuPont Biomedical Products Division, advancing to executive positions in marketing and product development at Centocor, GlaxoSmithKline, Endo Pharmaceuticals, and IMS Health.

Much of that work involved bringing new products through the long development and regulation-heavy process from concept to launch, with experience in therapeutic areas including oncology, urology, pain medicine, cardiology, and rheumatology. In an industry of specialty silos, Travers developed a uniquely blended expertise in marketing and R&D.

It was on March 23, 2006, that her health-care vocation turned personal: Travers, then a 50-year-old mother of two, was diagnosed with breast cancer.

An oncologist recommended a double mastectomy, removal of both ovaries, and chemotherapy. The tearful pleadings of her daughter, Kelly, then 18 I need you here when I graduate college, when I get married, when I have kids persuaded Travers to follow that recommendation.

She returned to work at Endo for seven more years, as a director in project management, before being laid off in June 2013, one month before her daughters wedding. The break gave Travers time to concentrate on the big event and to start to think what Id like to do when I grow up.

That process would lead her in late 2015 to PolyAurum, a start-up spun out of the University of Pennsylvania.

I became a CEO and a grandmother in the same year, said Travers, now 61, chuckling during a recent interview at the Pennovation Center incubator in West Philadelphia. From there, her home in Delaware, and the sites of pitch opportunities with investors, she is working to raise $1.3 million in seed funding by early in the fourth quarter, to help get PolyAurum closer to clinical trials on humans.

So far, research and testing funded through $4 million in grants to the university has been limited to mice with tumors. It has shown that gold nanocrystals less than five millimeters in diameter greatly enhance the effectiveness of radiation on tumors without increasing harm to healthy surrounding tissue, said Jay Dorsey, an associate professor and radiation oncologist at Penn and one of four university faculty who developed the technology.

The effectiveness of metals in improving a tumors ability to absorb radiation has long been known, Dorsey said. But one of the stumbling blocks to incorporating gold nanoparticles in such therapeutics is that the metal is not eliminated from the body well, posing serious problems to vital organs such as the liver and spleen.

Penns David Cormode, a professor of radiology, and Andrew Tsourkas, a professor of bioengineering, have worked to make gold more biocompatible, resulting in PolyAurums current technology, Dorsey said. The gold nanocrystals are contained in a biodegradable polymer that allows enough metal to collect in a tumor. The polymer then breaks down, releasing the gold for excretion from the body so that it does not build up in key organs.

The companys name is a combination of those two essential ingredients: Poly, derived from polymer, and Aurum, the Latin word for gold.

Explaining all that, and the potential that PolyAurums founders see for extending and saving lives, is the message Travers now is in charge of disseminating the part of the critical path to commercialization that is not the strength of most researchers toiling in laboratories.

She knows what the founders dont know it just makes a perfect match, said Michael Dishowitz, portfolio manager at PCI Ventures, an arm of Penn that helps university start-ups find investors, recruit management, and get to market.

Since its formation about eight years ago, PCI has helped more than 150 companies secure more than $100 million in funding, said Dishowitz, who has a doctoratein bioengineering from Penn and spent several years studying the impact of cell-signaling pathways on orthopedic injury.

While calling PolyAurums technology cool and very transformative for treatment, Dishowitz also delivered a dose of reality about the rigors ahead, as health-care start-ups must navigate a course with no guarantees their products will lead to actual clinical implementation.

PolyAurum is one of 13 companies that entered Philadelphia Media Networks second annual Stellar StartUps competition in the health-care/life sciences category. A total of nine categories drew 88 applicants. The winners will be announced Sept. 12 at an event at the Franklin Institutes Fels Planetarium. (Details at http://www.philly.com/stellarstartups.)

A lot has to go right, all the planets and stars have to align for this to hit the market, Dishowitz said of PolyAurums commercial prospects.

Which is why the team behind any start-up is so essential to investors, he said, calling Travers interest in joining a company that has yet been unable to pay her (she has equity in PolyAurum) incredibly lucky.

Margo Reed

At the Nanomedicine and Molecular Imaging Lab at Penn Medicine are (front row, from left) Jay Dorsey, a radiation oncologist and a founder of PolyAurum; Debra Travers, CEO; and Andrew Tsourkas, another founder of PolyAurum; and (back row, from left) Michael Dishowitz, portfolio manager, PCI Ventures at Penn; and David Cormode, lab director and PolyAurum founder. (MARGO REED / Staff Photographer)

The only thing Travers corporate-heavy background lacked, he said, was raising money for a start-up. It doesnt worry him, Dishowitz said, citing Travers perseverance, no-quit attitude.

When youre out there raising money, youre going to hear no about 100, 150 times before you hear yes, Dishowitz said.

When it comes to pitching for PolyAurum, Travers has extra incentive.

I am working on a cancer therapeutic, which is very important to the 11-year cancer survivor in me, she said.

As for handling nos, shes had plenty of professional experience with that.

After spending 30-plus years in the drug and diagnostic industries, where it is hard to find women CEOs or board members, Travers said, Ive learned to ignore the negative voices.

When: 5:30-8:30 p.m. Tuesday, Sept. 12.

Where: Fels Planetarium, Franklin Institute, 222 N. 20th St., Philadelphia 19103

For more information: http://www.philly.com/stellarstartups

Published: July 28, 2017 3:01 AM EDT

We recently asked you to support our journalism. The response, in a word, is heartening. You have encouraged us in our mission to provide quality news and watchdog journalism. Some of you have even followed through with subscriptions, which is especially gratifying. Our role as an independent, fact-based news organization has never been clearer. And our promise to you is that we will always strive to provide indispensable journalism to our community. Subscriptions are available for home delivery of the print edition and for a digital replica viewable on your mobile device or computer. Subscriptions start as low as 25 per day.We're thankful for your support in every way.

See original here:
Cancer survivor becomes a cancer fighter at a Philly start-up - Philly.com

Read the Rest...

Nanomedicine Opens Door to Precision Medicine for Brain Tumors – Northwestern University NewsCenter

§ July 13th, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine Opens Door to Precision Medicine for Brain Tumors – Northwestern University NewsCenter

The new therapeutic strategy involves injecting lipid polymer-based nanoparticles into glioblastoma brain tumors. The nanoparticle platform delivers molecules to the tumors that shut down key cancer drivers called brain tumor-initiating cells.

Early phase Northwestern Medicine research published in the journal Proceedings of the National Academy of Sciences has demonstrated a potential new therapeutic strategy for treating deadly glioblastoma brain tumors.

The strategy involves using lipid polymer-based nanoparticles to deliver molecules to the tumors, where the molecules shut down key cancer drivers called brain tumor-initiating cells (BTICs).

BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy, explained the studys first author, Dou Yu, MD, PhD, research assistant professor of Neurological Surgery.

Using mouse models of brain tumors implanted with BTICs derived from human patients, the scientists injected nanoparticles containing small interfering RNA (siRNA) short sequences of RNA molecules that reduce the expression of specific cancer-promoting proteins directly into the tumor. In the new study, the strategy stopped tumor growth and extended survival when the therapy was administered continuously through an implanted drug infusion pump.

This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind, said Yu, who collaborated on the research with principal investigatorMaciej Lesniak, MD, Michael J. Marchese Professor of Neurosurgery and chair of the Department of Neurological Surgery.

Maciej Lesniak, MD, Michael J. Marchese Professor of Neurosurgery and chair of the Department of Neurological Surgery, and Dou Yu, MD, PhD, research assistant professor of Neurological Surgery, were the senior and first authors of the new paper.

Glioblastoma is particularly difficult to treat because its genetic makeup varies from patient to patient. This new therapeutic approach would make it possible to deliver siRNAs to target multiple cancer-causing gene products simultaneously in a particular patients tumor.

In this study, the scientists tested siRNAs that target four transcription factors highly expressed in many glioblastoma tissues but not all. The therapy worked against classes of glioblastoma BTICs with high levels of those transcription factors, while other classes of the cancer did not respond.

This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling, Yu said. Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits.

The strategy could also apply to other medical conditions related to the central nervous system not just brain tumors.

Degenerative neurological diseases or even psychiatric conditions could potentially be the therapeutic candidates for this multiplexed delivery platform, Yu said.

Before scientists can translate this proof-of-concept research to humans, they will need to continue refining the nanomedicine platform and evaluating its long-term safety. Still, the findings from this new research provide insight for further investigation.

Nanomedicine provides a unique opportunity to advance a therapeutic strategy for a disease without a cure. By effectively targeting brain tumor-initiating stem cells responsible for cancer recurrence, this approach opens up novel translational approaches to malignant brain cancer, Lesniak summed up.

Yu and Lesniak, both members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, collaborated on this research with scientists at the Massachusetts Institute of Technology, Harvard University and Northwesterns McCormick School of Engineering.

This study was supported by the National Institutes of Healths National Cancer Institute Outstanding Investigator Award R35CA197725, a Burroughs Wellcome Collaborative Travel Grant, an Elsa U. Pardee Foundation grant, and a Northwestern University I3 Pilot Grant.

See original here:
Nanomedicine Opens Door to Precision Medicine for Brain Tumors - Northwestern University NewsCenter

Read the Rest...

Precision NanoSystems to Host Nanomedicines Symposium – Technology Networks

§ July 13th, 2017 § Filed under Nano Medicine Comments Off on Precision NanoSystems to Host Nanomedicines Symposium – Technology Networks

Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15th of July in Boston, MA. Following the success of last years inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Societys Annual Meeting and Exposition from the 16th to 18th of July.

The symposium schedule has been designed to provide an overview of the latest developments in nanomedicine research, including strategies for overcoming in vitro and in vivo barriers to effective and targeted drug delivery. It will cover a diverse range of applications, with the keynote address To target or not to target: lessons from RNAi-based targeted lipid nanoparticles being provided by Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. Other topics covered during the symposium will explore cutting-edge research in the fields of gene therapy, genetic vaccines and small molecule delivery. This will include industry talks from GSK, CureVac and Genentech, as well as presentations from the Beth Israel Deaconess Medical Centre, the University of British Columbia and Houston Methodist/Weill Cornell Medical College.

The symposium will also give attendees a chance to explore the latest enabling technologies in the nanomedicines sector with presentations from Precision NanoSystems and event sponsors Spectradyne, SpectrumLabs, Malvern Instruments and Sigma-Aldrich as well as providing networking opportunities throughout the day.

View post:
Precision NanoSystems to Host Nanomedicines Symposium - Technology Networks

Read the Rest...

Precision NanoSystems to host nanomedicines symposium – European Pharmaceutical Review

§ July 11th, 2017 § Filed under Nano Medicine Comments Off on Precision NanoSystems to host nanomedicines symposium – European Pharmaceutical Review

news

Join Precision NanoSystems for its second annual nanomedicines symposium

Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15of July in Boston, MA. Following the success of last years inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Societys Annual Meeting and Exposition from the 16to 18of July.

The symposium schedule has been designed to provide an overview of the latest developments in nanomedicine research, including strategies for overcoming in vitro and in vivo barriers to effective and targeted drug delivery. It will cover a diverse range of applications, with the keynote address To target or not to target: lessons from RNAi-based targeted lipid nanoparticles being provided by Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. Other topics covered during the symposium will explore cutting-edge research in the fields of gene therapy, genetic vaccines and small molecule delivery. This will include industry talks from GSK, CureVac and Genentech, as well as presentations from the Beth Israel Deaconess Medical Centre, the University of British Columbia and Houston Methodist/Weill Cornell Medical College.

The symposium will also give attendees a chance to explore the latest enabling technologies in the nanomedicines sector with presentations from Precision NanoSystems and event sponsors Spectradyne, SpectrumLabs, Malvern Instruments and Sigma-Aldrich as well as providing networking opportunities throughout the day.

For those unable to attend the event in person, you can still enjoy a virtual front row seat via a free livestream. Register now to join the event online.

Go here to see the original:
Precision NanoSystems to host nanomedicines symposium - European Pharmaceutical Review

Read the Rest...

Koch Institute’s Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer – AZoNano

§ July 10th, 2017 § Filed under Nano Medicine Comments Off on Koch Institute’s Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer – AZoNano

Written by AZoNanoJul 10 2017

The Koch Institute for Integrative Cancer Research at MIT will soon be reaching the first anniversary of the launch of the Marble Center for Cancer Nanomedicine, founded through a generous gift from Kathy and Curt Marble 63.

The Marble Center for Cancer Nanomedicines faculty is made up of Koch Institute members who are committed to fighting cancer with nanomedicine through research, education, and collaboration. Top row (l-r) Sangeeta Bhatia, director; Daniel Anderson; and Angela Belcher. Bottom row: Paula Hammond; Darrell Irvine; and Robert Langer. (Photo: Koch Institute Marble Center for Cancer Nanomedicine)

Bringing together leading Koch Institute faculty members and their teams, the Marble Center for Cancer Nanomedicine focuses on huge challenges in cancer detection, treatment and monitoring that can profit from the latest physics and biology of the nanoscale.

These challenges include spotting cancer earlier than present techniques allow, harnessing the immune system to combat cancer even as it progresses, using therapeutic insights from cancer biology to design therapies for formerly undruggable targets, integrating current drugs for synergistic action, and developing tools for more accurate diagnosis and improved surgical intervention.

Koch Institute member Sangeeta N. Bhatia, the John J. and Dorothy Wilson, Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, serves as the Inaugural Director of the center.

A major goal for research at the Marble Center is to leverage the collaborative culture at the Koch Institute to use nanotechnology to improve cancer diagnosis and care in patients around the world.

Sangeeta N. Bhatia, Koch Institute Member

Transforming nanomedicine

The Marble Center joins MITs larger efforts at the forefront of discovery and advancement to solve the critical global challenge that is cancer. The concept of convergence the combination of the life and physical sciences with engineering is a trademark of MIT, the founding principle of the Koch Institute, and at the heart of the Marble Centers mission.

The center galvanizes the MIT cancer research community in efforts to use nanomedicine as a translational platform for cancer care. Its transformative by applying these emerging technologies to push the boundaries of cancer detection, treatment, and monitoring and translational by promoting their development and application in the clinic.

Tyler Jacks, Director of the Koch Institute and a David H. Koch Professor of Biology

The centers faculty six renowned MIT Professors and Koch Institute Members are committed to combating cancer with nanomedicine through research, education and partnership. They are, Sangeeta Bhatia (director), the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science; Daniel G. Anderson, the Samuel A. Goldblith Professor of Applied Biology in the Department of Chemical Engineering and the Institute for Medical Engineering and Science; Angela M. Belcher, the James Mason Crafts Professor in the departments of Biological Engineering and Materials Science and Engineering; Paula T. Hammond, the David H. Koch Professor of Engineering and head of the Department of Chemical Engineering; Darrell J. Irvine, Professor in the departments of Biological Engineering and Materials Science and Engineering; and Robert S. Langer, the David H. Koch Institute Professor.

Extending their partnership within the walls of the Institute, members of the Marble Center profit greatly from the support of the Peterson (1957) Nanotechnology Materials Core Facility in the Koch Institutes Robert A. Swanson (1969) Biotechnology Center. The Peterson Facilitys array of technological resources and know-how is unparalleled in the United States, and gives members of the center and of the Koch Institute, a distinctive advantage in the development and application of materials and technologies at the nanoscale.

Looking ahead

The Marble Center made the most of its first year, and has provided backing for advanced research projects including theranostic nanoparticles that can both detect and treat cancers, real-time imaging of interactions between cancer and immune cells to properly understand reaction to cancer immunotherapies, and delivery technologies for a number of powerful RNA-based therapeutics capable of engaging specific cancer targets with precision.

As part of its efforts to help adopt a multifaceted science and engineering research force, the center has offered fellowship support for trainees as well as valuable opportunities for scientific exchange, mentorship and professional development.

Promoting wider engagement, the Marble Center serves as a bridge to a broad network of nanomedicine resources, linking its members to MIT.nano, other Nanotechnology Researchers, and Clinical Partners across Boston and beyond. The center has also set up a scientific advisory board, whose members come from leading clinical and academic centers around the country, and will assist in shaping the centers future programs and continued development.

As the Marble Center enters another year of partnerships and innovation, there is a new landmark in sight for 2018. Nanomedicine has been chosen as the main theme for the Koch Institutes 17th Annual Cancer Research Symposium. The event is scheduled for June 15th, 2018, and will bring together national domain experts, providing a perfect forum for Marble Center members to share the discoveries and progresses made during its sophomore year.

Having next years KI Annual Symposium dedicated to nanomedicine will be a wonderful way to further expose the cancer research community to the power of doing science at the nanoscale. The interdisciplinary approach has the power to accelerate new ideas at this exciting interface of nanotechnology and medicine.

Sangeeta N. Bhatia, Koch Institute Member

More:
Koch Institute's Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer - AZoNano

Read the Rest...

Semiconductor-laced bunny eyedrops appear to nuke infections – The Register

§ July 8th, 2017 § Filed under Nano Medicine Comments Off on Semiconductor-laced bunny eyedrops appear to nuke infections – The Register

Don't worry, little guy. They're really, really small!

In early lab experiments on rabbits, eyedrops laced with nanoparticles appear to combat bacterial keratitis, a serious infection of the cornea which can, in severe cases, cause blindness.

Researchers hope that these nanoparticles could someday offer a non-toxic alternative to antibiotics, which have the undesirable side effect of creating resistant bacteria.

A common treatment option is steroids, but they can cause scarring. Boffins have found that some nanomaterials, such as copper oxide and silicon, appear to damage bacterial cells. Lately, some groups have realised that carbon quantum dots really tiny semiconductors seem to offer similar benefits with low toxicity, the ability to disperse in water easily, and a relatively simple fabrication process.

"We think it should be safe," Han-Jia Lin, a biochemist at National Taiwan Ocean University in Keelung, told The Register. He and his team had previously studied quantum dots for wound healing in rats.

In the new study, Lin and his team created carbon quantum dots approximately six nanometers in diameter by heating spermidine at around 200oC for about three hours and placing the resultant dots in liquid. The ratio was about 0.4 per cent quantum dot to liquid.

The team infected rabbits with bacterial keratitis. Some received 4 per cent SMX antibiotics, some the quantum-filled eye drops, and others no treatment for control. The researchers found that the quantum dot eyedrop solution showed therapeutic effects right away, even after the first day. The dots were small enough to sneak into the cornea and destroy the bacterial cells.

This had something to do with the quantum dots' compatibility with the cells as well as how they destabilised the cell membranes. The researchers don't know exactly why they work.

By two weeks, the rabbits' eyes were mostly better the quantum dot eyedrop worked about as well as antibiotics. Lin says the treated rabbits showed no side effects from treatment.

A paper describing the research appeared this week in ACS Nano.

It's a "conceptually and technically quite elegant study with remarkable results" but "still with a couple of open questions and obvious risks before this could lead to any product that could help patients," Claus-Michael Lehr, a nanomedicine researcher at Saarland University in Saarbrcken, Germany, told The Reg.

First, he said the reasons why the nanomedicine has such strong bactericidal effects is "not easily explained". Second, the effect of opening tight junction tissue barriers (a potential risk in itself) needs to be shown to be reversible. Third, what chemical products are formed by the quantum dots are they toxic or carcinogenic?

Finally, he said it was wasn't clear how quantum dots that penetrate tissue would behave in the long term. "These structures are probably not biodegradable," he said, "and if they were, what metabolites are being formed?"

Lin says the next steps are to test the long-term effects of the quantum dots, but the the team is trying to be careful in their research to try to limit how they accumulate in bodies. Here, for example, they tested them on the eye.

Because the carbon quantum dots work on such a sensitive part of the body such as the eye without apparently harming cells, "This has potential," Lin said.

See original here:
Semiconductor-laced bunny eyedrops appear to nuke infections - The Register

Read the Rest...

Converging on cancer at the nanoscale – The MIT Tech

§ July 8th, 2017 § Filed under Nano Medicine Comments Off on Converging on cancer at the nanoscale – The MIT Tech

This summer, the Koch Institute for Integrative Cancer Research at MIT marks the first anniversary of the launch of the Marble Center for Cancer Nanomedicine, established through a generous gift from Kathy and Curt Marble 63.

Bringing together leading Koch Institute faculty members and their teams, the Marble Center for Cancer Nanomedicine focuses on grand challenges in cancer detection, treatment, and monitoring that can benefit from the emerging biology and physics of the nanoscale.

These challenges include detecting cancer earlier than existing methods allow, harnessing the immune system to fight cancer even as it evolves, using therapeutic insights from cancer biology to design therapies for previously undruggable targets, combining existing drugs for synergistic action, and creating tools for more accurate diagnosis and better surgical intervention.

Koch Institute member Sangeeta N. Bhatia, the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, serves as the inaugural director for the center.

A major goal for research at the Marble Center is to leverage the collaborative culture at the Koch Institute to use nanotechnology to improve cancer diagnosis and care in patients around the world, Bhatia says.

Transforming nanomedicine

The Marble Center joins MITs broader efforts at the forefront of discovery and innovation to solve the urgent global challenge that is cancer. The concept of convergence the blending of the life and physical sciences with engineering is a hallmark of MIT, the founding principle of the Koch Institute, and at the heart of the Marble Centers mission.

The center galvanizes the MIT cancer research community in efforts to use nanomedicine as a translational platform for cancer care, says Tyler Jacks, director of the Koch Institute and a David H. Koch Professor of Biology. Its transformative by applying these emerging technologies to push the boundaries of cancer detection, treatment, and monitoring and translational by promoting their development and application in the clinic.

The centers faculty six prominent MIT professors and Koch Institute members are committed to fighting cancer with nanomedicine through research, education, and collaboration. They are:

Sangeeta Bhatia (director), the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science;

Daniel G. Anderson, the Samuel A. Goldblith Professor of Applied Biology in the Department of Chemical Engineering and the Institute for Medical Engineering and Science;

Angela M. Belcher, the James Mason Crafts Professor in the departments of Biological Engineering and Materials Science and Engineering;

Paula T. Hammond, the David H. Koch Professor of Engineering and head of the Department of Chemical Engineering;

Darrell J. Irvine, professor in the departments of Biological Engineering and Materials Science and Engineering; and

Robert S. Langer, the David H. Koch Institute Professor.

Extending their collaboration within the walls of the Institute, Marble Center members benefit greatly from the support of the Peterson (1957) Nanotechnology Materials Core Facility in the Koch Institutes Robert A. Swanson (1969) Biotechnology Center. The Peterson Facilitys array of technological resources and expertise is unmatched in the United States, and gives members of the center, and of the Koch Institute, a distinct advantage in the development and application of nanoscale materials and technologies.

Looking ahead

The Marble Center has wasted no time getting up to speed in its first year, and has provided support for innovative research projects including theranostic nanoparticles that can both detect and treat cancers, real-time imaging of interactions between cancer and immune cells to better understand response to cancer immunotherapies, and delivery technologies for several powerful RNA-based therapeutics able to engage specific cancer targets with precision.

As part of its efforts to help foster a multifaceted science and engineering research force, the center has provided fellowship support for trainees as well as valuable opportunities for mentorship, scientific exchange, and professional development.

Promotingbroader engagement, the Marble Center serves as a bridge to a wide network of nanomedicine resources, connecting its members to MIT.nano, other nanotechnology researchers, and clinical collaborators across Boston and beyond. The center has also convened a scientific advisory board, whose members hail from leading academic and clinical centers around the country, and will help shape the centers future programs and continued expansion.

As the Marble Center begins another year of collaborations and innovation, there is a new milestone in sight for 2018.Nanomedicine has been selected as the central theme for the Koch Institutes 17th Annual Cancer Research Symposium. Scheduled for June 15, 2018, the event will bring together national leaders in the field, providing an ideal forum for Marble Center members to share the discoveries and advancements made during its sophomore year.

Having next years KI Annual Symposium dedicated to nanomedicine will be a wonderful way to further expose the cancer research community to the power of doing science at the nanoscale, Bhatia says. The interdisciplinary approach has the power to accelerate new ideas at this exciting interface of nanotechnology and medicine.

To learn more about the people and projects of the Koch Institute Marble Center for Cancer Nanomedicine, visit nanomedicine.mit.edu.

Excerpt from:
Converging on cancer at the nanoscale - The MIT Tech

Read the Rest...

Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

§ July 6th, 2017 § Filed under Nano Medicine Comments Off on Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

A Sample of this Report is Available Upon Request @http://www.persistencemarketresearch.com/samples/6370

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

Request to View Tables of Content @http://www.persistencemarketresearch.com/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

To Know About Latest Report Click Here:http://www.persistencemarketresearch.com/market-research/healthcare-nanotechnology-nanomedicine-market.asp

View original post here:
Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence ... - MilTech

Read the Rest...

Nanoparticle delivery tech targets rare lung disease – In-PharmaTechnologist.com

§ July 6th, 2017 § Filed under Nano Medicine Comments Off on Nanoparticle delivery tech targets rare lung disease – In-PharmaTechnologist.com

Researchers at London, UK-based Imperial College are developing a technology to transport drugs directly to the lungs of pulmonary arterial hypertension (PAH) patients.

The technology consists of ethanol-heated iron and trans-trans muconic acid nanoparticles that can be small molecule drug actives.

These particles can be delivered directly to the site of the disease according to lead researcher Jane Mitchell, who told us the targeted approach bypasses the toxicity issues that have held back development of less targeted, systemic nanomedicines.

One of the biggest limitations in nanomedicine is toxicity, some of the best nanomedicine structures do not make it past the initial stages of development, as they kill cells, said Mitchell.

However in a study published in Pulmonary Circulation , researchers explain that these metallic structures - called metal organic frameworks (MOF) are not harmful to cells.

We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells, Mitchell told us.

The hope is that using this approach will ultimately allow for high concentrations of drugs we already have, to be delivered to only the vessels in the lung, and reduce side effects, she said.

Pulmonary arterial hypertension (PAH)

PAH is a rare lung disease caused by changes to the smaller branches of the pulmonary arteries. The artery walls thicken, and eventually cause organ failure.

While no cure exists, treatments that open up blood vessels in the artery wall are available. According to Mitchell, these treatments can produce negative side effects.

The drugs available [for PAH]are all small molecule drugs which are seriously limited by systemic side effects. Therefore delivering these drugs to the site of disease in our metal organic frame-work (MOF) carrier would represent a paradigm step forward in technology to treat this disease, she said.

Further, researchers believe the MOF technology has therapeutic benefits of its own.

We know that the carriers can havetherapeutic benefits intheir own right such as reducing inflammation and, in the case of ourformation, the potential for imaging, said Mitchell.

For patients with PAH, it could mean we are able to turn it from a fatal condition, to a chronic manageable one, she said.

According to Mitchell, the technology is not expensive at the experimental level, and would be scaled up at commercial level.

We now need to perform proof of concept studies using carriers containing drugs in cell and animal based models. With funding, this will be complete within 2 years, she Mitchell.

Upon completion of clinical trials, the University hopes to license out the technology.

Read the original here:
Nanoparticle delivery tech targets rare lung disease - In-PharmaTechnologist.com

Read the Rest...

Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 – PR Newswire (press release)

§ July 6th, 2017 § Filed under Nano Medicine Comments Off on Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 – PR Newswire (press release)

LONDON, July 5, 2017 /PRNewswire/ -- "Global Nano Chemotherapy Market & Clinical Trials Outlook 2022" report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.

Download the full report: https://www.reportbuyer.com/product/4884894/

Nano chemotherapy is emerging as an important anti-cancer modality by supplementing the traditional chemotherapy. The main aim of nano chemotherapeutics is to improve the therapeutic efficacy of currently available chemotherapeutic agents by combining it with a nano scale delivery component. The majority of the cancer nanodrugs in the market are liposomes and polymer based nanoformulations which lower the toxicity and enhance the delivery of chemotherapeutics through the passive targeting. It is based on enhanced penetration and retention effect to reduce the lymphatic drainage in tumor tissue.

Conventional chemotherapeutic agents are distributed non-specifically in body where they affect both cancerous and normal cells and thereby it limit the dose availability with in the tumor and also results in suboptimal treatment due to excessive toxicities. To overcome the limitations of chemotherapy treatment, many more therapies has also been emerged.

The use of nanoparticles by both passive and active targeting strategies can enhance the intracellular concentration of drugs in cancer cells while avoiding the toxicity in normal cells. When the nanoparticles bind to a specific receptors and then enter the cell, usually enveloped by endosomes through receptor mediated endocytosis and thereby bypassing the recognition of P glycoprotein.

Nanomedicine has already met with success in oncology domain with various product commercially available in the market. By releasing the efficacy of nanomedicine in oncology, it increases the interest of the market players to commercialize the products in the field of nanotherapeutics and helps to increase the global market. The future of nanotherapeutics is bright and especially for the reversible cross linked nano carriers which are decorated with the cancer targeting ligands and it promote the endocytic uptake in tumor cells. The approach has the potential to overcome the drug resistance which is often with conventional chemotherapies.

For the next generation cancer nanotherapeutics, the complexity is higher which are under clinical development in terms of hybrid structures, surface physiochemical characteristics and mechanisms of delivery and action. There have been rapid advances in the nano therapeutic field in the past decade. Many of the nano carriers have been developed from which some have the great therapeutic potential. However, there remain many challenges in translating the nanoparticle drugs into the clinics. Download the full report: https://www.reportbuyer.com/product/4884894/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-nano-chemotherapy-market--clinical-trials-outlook-2022-300483678.html

More:
Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 - PR Newswire (press release)

Read the Rest...

Metallic nanomolecules could help treat fatal lung disease in the future, notes research – EPM Magazine

§ July 5th, 2017 § Filed under Nano Medicine Comments Off on Metallic nanomolecules could help treat fatal lung disease in the future, notes research – EPM Magazine

New research from Imperial College London, that has recently been published online, examined a novel type of nanoparticle called metal organic frameworks (MOF) as drug carriers for the treatment of pulmonary arterial hypertension (PAH).

Published in Pulmonary Circulation, the research describes the first steps in the development of nanoparticles that can deliver drugs directly to the lungs. The MOFs, created in the laboratory by the researchers, are composed of iron and can expand to create pores within which drugs used to treat PAH can be stored and released where needed.

The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects, explained Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial in a news release. For patients with PAH, it could mean we are able to turn it from a fatal condition, to a chronic manageable one.

When testing the MOFs, the team from Imperial found that the structures reduced inflammation and were not toxic to human lung cells and blood vessels in laboratory conditions. Further testing in rats, showed the MOFs were safe in the animal model over a two-week period with few side-effects a slight build-up of iron was seen in the liver.

One of the biggest limitations in nanomedicine is toxicity, some of the best nanomedicine structures do not make it past the initial stages of development as they kill cells, continued Mitchell. We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells.

The aim is to develop the metallic structures as a drug delivery method where the framework can hold onto the drug and release it under specific conditions, such as a change in pH, temperature or using magnets external to the body to draw the MOFs to the target area. Next steps for this research is to discover the ideal way to get the tiny structures loaded with drugs and delivered to the lungs effectively.

In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung, Mitchell concluded. This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery.

See the original post:
Metallic nanomolecules could help treat fatal lung disease in the future, notes research - EPM Magazine

Read the Rest...

Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

§ July 3rd, 2017 § Filed under Nano Medicine Comments Off on Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

July 3, 2017 by Ryan O'hare Nanomedicine could help patients with fatal lung conditions. Credit: Imperial College London

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

Scientists based at Imperial College London have tested a new type of nanoparticle called metal organic frameworks (MOF) tiny metal cages less than 100 nanometres across that can be loaded with drug molecules which they believe could potentially be used to treat patients with a devastating condition called pulmonary arterial hypertension (PAH).

In PAH the blood vessels of the lungs constrict and thicken, increasing blood pressure and causing the right side of the heart to work harder and harder, until it eventually fails. The condition is rare but devastating and can affect people of all ages, including babies, young adults and the elderly. Patients in the late stage of the disease have few treatment options beyond transplant, with a mean survival time of around five years following diagnosis.

While there is no cure for PAH, existing treatments work by opening up these blood vessels. These drugs act on blood vessels throughout the body, however, causing blood pressure to drop and resulting in a number of side effects which means the dose at which these drugs can be given is limited.

In their latest study, published online in Pulmonary Circulation, the multidisciplinary group at Imperial describes how it has taken the first in a number of steps to develop nanoparticles which could deliver drugs directly to the lungs, showing that the basic structures are not harmful to cells.

Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial, who led the research, said: "The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects. For patients with pulmonary arterial hypertension, it could mean we are able to turn it from a fatal condition, to a chronic manageable one."

Metallic cages for drug delivery

The tiny metallic structures composed of iron were made in the lab of Professor Paul Lickiss and Dr Rob Davies's, from the Department of Chemistry and by Dr Nura Mohamed during her PhD studies at Imperial. Dr Mohamed, who was funded by the Qatar Foundation, made the structures so existing drugs used to treat PAH could fit inside them.

These structures were tested in human lung cells and blood vessel cells, which were grown from stem cells in the blood of patients with PAH. The team found that the structures reduced inflammation and were not toxic to the cells.

Further tests showed that the MOFs were safe in rats, with animals injected with MOFs over a two-week period showing few side effects other than a slight build-up of iron in the liver.

"One of the biggest limitations in nanomedicine is toxicity, some of best nanomedicine structures do not make it past the initial stages of development as they kill cells," said Professor Mitchell. "We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells."

MOFs are an area of interest in nanomedicine, with engineers aiming to develop them as carriers which can hold onto drug cargo, releasing it under specific conditions, such as changes in pH, temperature, or even when the nanostructures are drawn to the target area by magnets outside the body.

Beyond the finding that their iron nanostructures were non-toxic, the team believes the MOFs may have additional therapeutic properties. There was evidence to suggest anti-inflammatory properties, with the MOFs reducing the levels of an inflammatory marker in the blood vessels, called endothelin-1, which causes arteries to constrict. In addition, iron is also a contrast agent, meaning it would show up on scans of the lungs to show where the drug had reached.

The MOFs have not yet been tested in patients, but the next step is to load the tiny metallic structures with drugs and work out the best way to get them to target their cargo to the lungs. The researchers are confident that if successful, the approach could move to trials for patients, with a drug candidate ready to test within the next five years. The MOFs could potentially be delivered by an inhaler into the lung, or administered by injection.

"In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung," explained Professor Mitchell. "This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery."

Explore further: Longer-lasting pain relief with MOFs

More information: Nura A. Mohamed et al. Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy, Pulmonary Circulation (2017). DOI: 10.1177/2045893217710224

To treat headaches, back pain or fever, most of us have reached for ibuprofen at one point or another. But we often have to take doses every four to six hours if the pain warrants it. Now scientists are working on a way to ...

People with a lung scarring condition that leaves them fighting for breath could be helped by a new medication, research suggests.

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for ...

(HealthDay)Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary ...

(Medical Xpress) -- Scientists at UCD have identified a potential new treatment for life-threatening complications associated with chronic obstructive lung diseases like emphysema and chronic bronchitis. Chronic obstructive ...

(Phys.org)One of the most promising microscale power sources for portable and wearable electronics is a micro-supercapacitorthey can be made thin, lightweight, highly flexible, and with a high power density. Normally, ...

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

The possibility of looking inside silicon chips to see their tiny working parts, without damaging the chips, is a step closer thanks to an international team led by scientists at the LCN.

Science fiction is full of fanciful devices that allow light to interact forcefully with matter, from light sabers to photon-drive rockets. In recent years, science has begun to catch up; some results hint at interesting ...

Dialysis, in the most general sense, is the process by which molecules filter out of one solution, by diffusing through a membrane, into a more dilute solution. Outside of hemodialysis, which removes waste from blood, scientists ...

Rice University scientists have fabricated a durable catalyst for high-performance fuel cells by attaching single ruthenium atoms to graphene.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Excerpt from:
Nano-sized drug carriers could be the future for patients with lung disease - Phys.Org

Read the Rest...

Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

§ June 30th, 2017 § Filed under Nano Medicine Comments Off on Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

June 30, 2017 Size switchable nano-theranostics constructed with decomposable inorganic nanomaterials for acidic TME targeted cancer therapy. (a) A scheme showing the preparation of HSA-MnO2-Ce6&Pt (HMCP) nanoparticles, and (b) their tumor microenvironment responsive dissociation to enable efficient intra-tumoral penetration of therapeutic albumin complexes. (c) A scheme showing the preparation of Ce6(Mn)@CaCO3-PEG, and (d) its acidic TME responsive dissociation for enhanced MR imaging and synergistic cancer therapy. Credit: Science China Press

Cancer is one of leading causes of human mortality around the world. The current mainstream cancer treatment modalities (e.g. surgery, chemotherapy and radiotherapy) only show limited treatment outcomes, partly owing to the complexities and heterogeneity of tumor biology. In recent decades, with the rapid advance of nanotechnology, nanomedicine has attracted increasing attention as promising for personalized medicine to enable more efficient and reliable cancer diagnosis and treatment.

Unlike normal cells energized via oxidative phosphorylation, tumor cells utilize the energy produced from oxygen-independent glycolysis for survival by adapting to insufficient tumor oxygen supply resulting from the heterogeneously distributed tumor vasculatures (also known as the Warburg effect). Via such oncogenic metabolism, tumor cells would produce a large amount of lactate along with excess protons and carbon dioxide, which collectively contribute to enhanced acidification of the extracellular TME with pH, often in the range of 6.5 to 6.8, leading to increased tumor metastasis and treatment resistance.

With rapid advances in nanotechnology, several catalogs of nanomaterials have been widely explored for the design of cancer-targeted nano-theranostics. In a new overview published in the Beijing-based National Science Review, co-authors Liangzhu Feng, Ziliang Dong, Danlei Tao, Yicheng Zhang and Zhuang Liu at the Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University in Suzhou, China present new developments in the design of novel multifunctional nano-theranostics for precision cancer nanomedicine by targeting the acidic TME and outline the potential development directions of future acidic tumor microenvironment-responsive nano-theranostics.

"Various types of pH-responsive nanoprobes have been developed to enable great signal amplification under slightly reduced pH within solid tumors. By taking the acidic TME as the target, smart imaging nanoprobes with excellent pH-responsive signal amplification would be promising to enable more sensitive and accurate tumor diagnosis," they state in the published study.

"As far as nano-therapeutics are concerned, it has been found that the acidic TME responsive surface charge reverse, PEG corona detachment and size shrinkage (or decomposition) of nanoparticles would facilitate the efficient tumor accumulation, intra-tumoral diffusion and tumor cellular uptake of therapeutics, leading to significantly improved cancer treatment. Therefore, the rational development of novel cancer-targeted nano-theranostics with sequential patterns of size switch from large to small, and surface charge reverse from neutral or slightly negative to positive within the tumor, would be more preferred for efficient tumor-targeted drug delivery."

The scientists also write, "For the translation of those interesting smart pH-responsive nano-therapeutics from bench to bedside, the formulation of those nanoscale systems should be relatively simple, reliable and with great biocompatibility, since many of those currently developed nano-theranostics were may be too complicated for clinical translation."

Explore further: Treatment with Alk5 inhibitor improves tumor uptake of imaging agents

More information: Liangzhu Feng et al, The acidic tumor microenvironment: a target for smart cancer nano-theranostics, National Science Review (2017). DOI: 10.1093/nsr/nwx062

A form of genetic variation, called differential RNA splicing, may have a role in tumor aggressiveness and drug resistance in African American men with prostate cancer. Researchers at the George Washington University (GW) ...

While mutations in protein-coding genes have held the limelight in cancer genomics, those in the noncoding genome (home to the regulatory elements that control gene activity) may also have powerful roles in driving tumor ...

A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study led by UC San Francisco in collaboration ...

Scientists have had limited success at identifying specific inherited genes associated with prostate cancer, despite the fact that it is one of the most common non-skin cancers among men. Researchers at University of Utah ...

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma develops when the body starts making abnormal B-cells, which are white ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:
Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics - Medical Xpress

Read the Rest...

MagForce AG Publishes Financial Results for the Year 2016 and Operative Highlights – Baystreet.ca

§ June 30th, 2017 § Filed under Nano Medicine Comments Off on MagForce AG Publishes Financial Results for the Year 2016 and Operative Highlights – Baystreet.ca

[ACCESSWIRE]

- Continued Expansion of Commercialization of NanoTherm Therapy for the Treatment of Brain Tumors in Europe; Obtaining Domestic Reimbursement Ahead and Streamlined Implementation of Cross-Border Process - Second Clinical Treatment Site for the Treatment of Intermediate Prostate Cancer in the US Established at CHRISTUS Santa Rosa Hospital - Medical Center in San Antonio, Texas; IDE Approval Process with the FDA Progressing - Successful Capital Increase with Renowned UK-Based M&G International Investments with Gross Proceeds of EUR 5.0 Million Mainly to Accelerate the On-Going International Expansion (After Period-End)

BERLIN, GERMANY and NEVADA / ACCESSWIRE / June 30, 2017 / MagForce AG (FRA: MF6, Scale: MF6, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results as of and for the year ended December 31, 2016 as well as operative highlights.

Operative Highlights:

Treatment of Brain Cancer in Europe:

MagForce AG is continuing to expand the commercialization of its innovative NanoTherm therapy for the treatment of brain cancer in Europe. In their quest to improve patient care, the neurosurgeons applying NanoTherm therapy for the treatment of brain tumors continue to find additional medical benefits when NanoTherm therapy is incorporated into their primary treatment regimen.

MagForce presented at many renowned conferences and congresses, which increases the awareness of its unique therapy within the main target groups, such as the medical community, patient advocacy groups, patients, their relatives, and caregivers. The Company is also increasingly receiving positive feedback from patients regarding their experiences with the NanoTherm therapy.

During 2016, MagForce has streamlined the implementation of the cross-border reimbursement process, however, due to the aggressiveness of glioblastoma, there is a limited time interval to achieve treatment. In order to give patients the benefit from the NanoTherm treatment, the Company continues to increase the medical awareness of the value of NanoTherm therapy to encourage patients and neurosurgeons to consider NanoTherm therapy earlier following the diagnosis of their tumor status.

The current roll-out plan sees MagForce placing its NanoActivator devices in a number of European countries and thus enabling patients to be treated in their home countries. Facilitating treatment of patients in their home countries will also simplify reimbursement in those countries where MagForce already has the CE mark approval for the treatment of brain tumors. Amongst others, MagForce's commercial and medical teams have identified Poland, Italy, Switzerland, and Spain as suitable countries for NanoTherm treatment centers.

At the same time, MagForce is in the process of obtaining domestic reimbursement for NanoTherm therapy in Germany.

Treatment of Intermediate Risk Prostate Cancer in the USA:

MagForce USA, Inc. had filed an Investigational Device Exemption (IDE) with the USA Food and Drug Administration (FDA) for NanoTherm therapy to treat Intermediate Risk Prostate Cancer. During 2016, MagForce USA repeated and updated the pre-clinical studies (originally conducted in Germany about 10 years ago) with its clinical NanoActivator installed at University of Washington 2015.

The results of these pre-clinical studies and the proposed clinical trial protocol were submitted to the FDA in late fourth quarter, 2016. An in-person follow-up meeting with FDA representatives was held in early January 2017 to discuss MagForce's submissions and identify required clarification. This meeting was again very productive and MagForce believes it can successfully address their questions.

MagForce plans another in-person meeting with the FDA in the near future to determine if its proposed approach to address their requests is accepted.

The key to achieving the Company's goals is to continue to establish clinical treatment sites and obtain the necessary administrative approvals. MagForce has completed the installation of the NanoActivator at a second site located at CHRISTUS Santa Rosa Hospital - Medical Center in San Antonio, Texas.

While MagForce is now approximately six months behind schedule, the Management is still confident and will make every effort to achieve its original targets in terms of market entry and commercialization of NanoTherm therapy in the USA - which is projected for 2018.

Results of Operations, Net Assets, and Financial Position

Non-GAAP financial measures are used by MagForce's management to make operating decisions because they facilitate internal comparisons of MagForce's performance to historical results. The Non GAAP measures are presented in the year-end financial publication as MagForce's management believes that they will provide investors with means of evaluating, and an understanding of how MagForce's management evaluates, MagForce's performance and results on a comparable basis that is not otherwise apparent on a German GAAP basis, since many non-recurring, infrequent or non-cash items that MagForce's management believes are not indicative of the core performance of the business may not be excluded when preparing financial measures under German GAAP.

These Non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with German GAAP.

Net Loss for the business year was EUR 7,231 thousand (prior year: EUR 1,547 thousand). Non-GAAP net loss remained almost stable at EUR 5,107 thousand (prior year: EUR 5,050 thousand).

Compared to the prior year period personnel expenses increased by EUR 262 thousand to EUR 3,252 thousand (prior year: EUR 2,990 thousand) due to an increased average number of employees in 2016 (29; prior year: 23).

Revenue and Other Operating Income amounted to EUR 1,581 thousand (prior year: EUR 7,702), while Non-GAAP revenue and other operating income increased by EUR 136 thousand to EUR 1,581 thousand (prior year: EUR 1,445 thousand). The Non-GAAP increase chiefly stems from higher recharges to subsidiaries. Revenue and other operating income were adjusted to arrive at Non-GAAP figures by the prior-year amounts resulting from the extension of the distribution and development rights for the countries Canada and Mexico in January 2015 (EUR 3,033 thousand), the sale of four NanoActivator devices to MagForce USA, Inc. (EUR 2,421 thousand) and by the write-up of the loans of MT MedTech GmbH (EUR 803 thousand).

Other operating expenses increased to EUR 4,309 thousand (prior year: EUR 3,173 thousand), while Non-GAAP operating expenses remained almost stable at EUR 6,918 thousand (prior year: EUR 6,824 thousand). Other operating expenses were adjusted for the impairment of the loans to MT MedTech GmbH in the amount of EUR 1,218 thousand (prior year: nil) to arrive at Non-GAAP.

Cash outflows from operating activities amounted to EUR -6,575 thousand (prior year: EUR -5,185 thousand).

Cash inflows from investing activities amounted to EUR 3,073 thousand (prior year: Cash outflow of EUR -2,575 thousand). Cash inflows for the year 2016 are largely due to repayments of short-term loans in the amount of EUR 3,000 thousand. Cash flows from financing activities amounted to EUR 2,723 (prior year: EUR nil).

Cash and cash equivalents as of December 31, 2016 amounted to EUR 614 thousand (prior year: EUR 1,393 thousand).

Capital Market Transactions and Funding of the Company After the End of Period

To improve liquidity and to ensure the development of new products beyond 2017 the Company issued a EUR 5.0 million convertible loan on March 2, 2017, with a maturity of 3 years, an interest rate of 5% p.a., and a conversion price at EUR 5.00 per share. Furthermore, Lipps & Associates LLC continues providing lines of funds to support expansion plans as a means of non-dilutive funding.

In addition on June 28, 2017, MagForce AG resolved and successfully implemented a capital increase from authorized capital. The Company's share capital will, therefore, be increased from EUR 25,622,711.00 to EUR 26,343,172.00 by issuing 720,461 new no-par-value shares at a price of EUR 6,94 per share by partially utilizing existing authorized capital against cash contributions. All new shares were subscribed by UK-based M&G International Investments Ltd. in a private placement. Gross proceeds for MagForce AG amount to EUR 5.0 million. The additional capital will be mainly used to accelerate the on-going international expansion of MagForce, in particular in Europe.

Outlook and Financial Prognosis 2017 and Beyond

In 2017, MagForce will focus on establishing an expansion strategy in Europe for the treatment of brain tumors, initiating a study to ensure refund of treatment expenses in selected European countries, starting the clinical study for marketing authorization for the treatment of prostate cancer in the US and initiating the production of related ambulatory NanoActivator devices.

The Company expects an extension of its business activity due to the planned expansion strategy in Europe. This is accompanied by a study to ensure reimbursement of treatment expenses in participating countries. As a result from the increased activity, MagForce expects higher commercial expenses and in 2018 an increased net loss.

For the years 2017 and 2018, the Company plans to intensify cooperation with local and international patient organizations to further establish NanoTherm therapy and to increase the number of patient inquiries. Furthermore, new ways for reimbursement in Germany and selected countries will be established to make NanoTherm therapy available to as many patients as possible. Also, the Company plans to enhance its presence at appropriate events and with foreign patient organizations. MagForce's management has executed the necessary measures and set up a plan to finance the Company's expansion targets for Europe in 2017 and 2018.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.com.

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects," "aims," "anticipates," "intends," "plans," "believes," "seeks," "estimates," or "will." Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in the case of developments, which differ from those, anticipated.

Contact:

Barbara von Frankenberg Vice President Communications & Investor Relations T +49-30-308380-77 E-Mail: bfrankenberg@magforce.com

SOURCE: MagForce AG via the EQS Newswire distribution service including Press Releases and Regulatory Announcements

See more here:
MagForce AG Publishes Financial Results for the Year 2016 and Operative Highlights - Baystreet.ca

Read the Rest...

« Older Entries Newer Entries »



Page 10«..9101112..2030..»